NCT02369484View on ClinicalTrials.gov

Afatinib in NSCLC With HER2 Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 16, 2015

Primary Completion Date

September 15, 2017

Study Completion Date

September 15, 2017

Conditions
NSCLC
Interventions
DRUG

Afatinib

40mg p.o./ day until documented progression or unacceptable toxicity

Trial Locations (5)

Unknown

Universitätsklinikum Köln, Cologne

NKI-AVL, Amsterdam

Vall d'Hebron University Hospital, Barcelona

CHUV, Lausanne

USZ, Zurich

All Listed Sponsors
lead

ETOP IBCSG Partners Foundation

NETWORK

NCT02369484 - Afatinib in NSCLC With HER2 Mutation | Biotech Hunter | Biotech Hunter